Medical - Healthcare Plans
Compare Stocks
2 / 10Stock Comparison
ELV vs CI
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Plans
ELV vs CI — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Healthcare Plans | Medical - Healthcare Plans |
| Market Cap | $80.15B | $72.68B |
| Revenue (TTM) | $200.41B | $277.94B |
| Net Income (TTM) | $5.24B | $6.29B |
| Gross Margin | 23.2% | 9.3% |
| Operating Margin | 3.8% | 3.4% |
| Forward P/E | 13.8x | 9.1x |
| Total Debt | $33.23B | $31.46B |
| Cash & Equiv. | $9.49B | $7.68B |
ELV vs CI — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Elevance Health Inc. (ELV) | 100 | 127.4 | +27.4% |
| Cigna Corporation (CI) | 100 | 142.9 | +42.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ELV vs CI
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ELV carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 12.6%, EPS growth -2.2%, 3Y rev CAGR 8.3%
- 202.3% 10Y total return vs CI's 124.1%
- 12.6% revenue growth vs CI's 11.3%
CI is the clearest fit if your priority is income & stability and sleep-well-at-night.
- Dividend streak 6 yrs, beta 0.35, yield 2.2%
- Lower volatility, beta 0.35, Low D/E 75.1%, current ratio 0.85x
- Beta 0.35, yield 2.2%, current ratio 0.85x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 12.6% revenue growth vs CI's 11.3% | |
| Value | Lower P/E (9.1x vs 13.8x) | |
| Quality / Margins | Combined ratio 1.0 vs CI's 1.0 (lower = better underwriting) | |
| Stability / Safety | Beta 0.35 vs ELV's 0.46, lower leverage | |
| Dividends | 2.2% yield, 6-year raise streak, vs ELV's 1.9% | |
| Momentum (1Y) | -9.7% vs CI's -15.4% | |
| Efficiency (ROA) | 4.3% ROA vs CI's 4.1%, ROIC 9.1% vs 10.4% |
ELV vs CI — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
ELV vs CI — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
ELV leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CI and ELV operate at a comparable scale, with $277.9B and $200.4B in trailing revenue. Profitability is closely matched — net margins range from 2.6% (ELV) to 2.3% (CI).
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $200.4B | $277.9B |
| EBITDAEarnings before interest/tax | $8.9B | $12.1B |
| Net IncomeAfter-tax profit | $5.2B | $6.3B |
| Free Cash FlowCash after capex | $6.5B | $7.7B |
| Gross MarginGross profit ÷ Revenue | +23.2% | +9.3% |
| Operating MarginEBIT ÷ Revenue | +3.8% | +3.4% |
| Net MarginNet income ÷ Revenue | +2.6% | +2.3% |
| FCF MarginFCF ÷ Revenue | +3.2% | +2.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +2.6% | +4.6% |
| EPS Growth (YoY)Latest quarter vs prior year | -16.8% | +29.1% |
Valuation Metrics
CI leads this category, winning 6 of 6 comparable metrics.
Valuation Metrics
At 12.4x trailing earnings, CI trades at a 15% valuation discount to ELV's 14.7x P/E. On an enterprise value basis, CI's 8.2x EV/EBITDA is more attractive than ELV's 10.8x.
| Metric | ||
|---|---|---|
| Market CapShares × price | $80.1B | $72.7B |
| Enterprise ValueMkt cap + debt − cash | $103.9B | $96.5B |
| Trailing P/EPrice ÷ TTM EPS | 14.69x | 12.43x |
| Forward P/EPrice ÷ next-FY EPS est. | 13.79x | 9.09x |
| PEG RatioP/E ÷ EPS growth rate | 2.12x | — |
| EV / EBITDAEnterprise value multiple | 10.76x | 8.20x |
| Price / SalesMarket cap ÷ Revenue | 0.40x | 0.26x |
| Price / BookPrice ÷ Book value/share | 1.86x | 1.75x |
| Price / FCFMarket cap ÷ FCF | 25.25x | 8.66x |
Profitability & Efficiency
CI leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
CI delivers a 15.1% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $12 for ELV. CI carries lower financial leverage with a 0.75x debt-to-equity ratio, signaling a more conservative balance sheet compared to ELV's 0.75x. On the Piotroski fundamental quality scale (0–9), CI scores 8/9 vs ELV's 6/9, reflecting strong financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +11.9% | +15.1% |
| ROA (TTM)Return on assets | +4.3% | +4.1% |
| ROICReturn on invested capital | +9.1% | +10.4% |
| ROCEReturn on capital employed | +8.2% | +9.2% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 8 |
| Debt / EquityFinancial leverage | 0.75x | 0.75x |
| Net DebtTotal debt minus cash | $23.7B | $23.8B |
| Cash & Equiv.Liquid assets | $9.5B | $7.7B |
| Total DebtShort + long-term debt | $33.2B | $31.5B |
| Interest CoverageEBIT ÷ Interest expense | 5.39x | 6.77x |
Total Returns (Dividends Reinvested)
Evenly matched — ELV and CI each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CI five years ago would be worth $11,658 today (with dividends reinvested), compared to $10,243 for ELV. Over the past 12 months, ELV leads with a -9.7% total return vs CI's -15.4%. The 3-year compound annual growth rate (CAGR) favors CI at 3.9% vs ELV's -5.8% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +4.7% | -0.7% |
| 1-Year ReturnPast 12 months | -9.7% | -15.4% |
| 3-Year ReturnCumulative with dividends | -16.3% | +12.2% |
| 5-Year ReturnCumulative with dividends | +2.4% | +16.6% |
| 10-Year ReturnCumulative with dividends | +202.3% | +124.1% |
| CAGR (3Y)Annualised 3-year return | -5.8% | +3.9% |
Risk & Volatility
Evenly matched — ELV and CI each lead in 1 of 2 comparable metrics.
Risk & Volatility
CI is the less volatile stock with a 0.35 beta — it tends to amplify market swings less than ELV's 0.46 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ELV currently trades 87.0% from its 52-week high vs CI's 81.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.46x | 0.35x |
| 52-Week HighHighest price in past year | $424.24 | $338.89 |
| 52-Week LowLowest price in past year | $273.71 | $239.51 |
| % of 52W HighCurrent price vs 52-week peak | +87.0% | +81.3% |
| RSI (14)Momentum oscillator 0–100 | 76.4 | 51.2 |
| Avg Volume (50D)Average daily shares traded | 1.9M | 1.6M |
Analyst Outlook
Evenly matched — ELV and CI each lead in 1 of 2 comparable metrics.
Analyst Outlook
Wall Street rates ELV as "Buy" and CI as "Buy". Consensus price targets imply 19.0% upside for CI (target: $328) vs 3.6% for ELV (target: $382). For income investors, CI offers the higher dividend yield at 2.20% vs ELV's 1.87%.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $382.38 | $328.00 |
| # AnalystsCovering analysts | 37 | 39 |
| Dividend YieldAnnual dividend ÷ price | +1.9% | +2.2% |
| Dividend StreakConsecutive years of raises | 15 | 6 |
| Dividend / ShareAnnual DPS | $6.89 | $6.06 |
| Buyback YieldShare repurchases ÷ mkt cap | +3.3% | +5.0% |
CI leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). ELV leads in 1 (Income & Cash Flow). 3 tied.
ELV vs CI: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is ELV or CI a better buy right now?
For growth investors, Elevance Health Inc.
(ELV) is the stronger pick with 12. 6% revenue growth year-over-year, versus 11. 3% for Cigna Corporation (CI). Cigna Corporation (CI) offers the better valuation at 12. 4x trailing P/E (9. 1x forward), making it the more compelling value choice. Analysts rate Elevance Health Inc. (ELV) a "Buy" — based on 37 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ELV or CI?
On trailing P/E, Cigna Corporation (CI) is the cheapest at 12.
4x versus Elevance Health Inc. at 14. 7x. On forward P/E, Cigna Corporation is actually cheaper at 9. 1x.
03Which is the better long-term investment — ELV or CI?
Over the past 5 years, Cigna Corporation (CI) delivered a total return of +16.
6%, compared to +2. 4% for Elevance Health Inc. (ELV). Over 10 years, the gap is even starker: ELV returned +202. 3% versus CI's +124. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ELV or CI?
By beta (market sensitivity over 5 years), Cigna Corporation (CI) is the lower-risk stock at 0.
35β versus Elevance Health Inc. 's 0. 46β — meaning ELV is approximately 30% more volatile than CI relative to the S&P 500. On balance sheet safety, Cigna Corporation (CI) carries a lower debt/equity ratio of 75% versus 75% for Elevance Health Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — ELV or CI?
By revenue growth (latest reported year), Elevance Health Inc.
(ELV) is pulling ahead at 12. 6% versus 11. 3% for Cigna Corporation (CI). On earnings-per-share growth, the picture is similar: Cigna Corporation grew EPS 82. 9% year-over-year, compared to -2. 2% for Elevance Health Inc.. Over a 3-year CAGR, CI leads at 15. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ELV or CI?
Elevance Health Inc.
(ELV) is the more profitable company, earning 2. 8% net margin versus 2. 2% for Cigna Corporation — meaning it keeps 2. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ELV leads at 4. 1% versus 3. 3% for CI. At the gross margin level — before operating expenses — ELV leads at 25. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ELV or CI more undervalued right now?
On forward earnings alone, Cigna Corporation (CI) trades at 9.
1x forward P/E versus 13. 8x for Elevance Health Inc. — 4. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CI: 19. 0% to $328. 00.
08Which pays a better dividend — ELV or CI?
All stocks in this comparison pay dividends.
Cigna Corporation (CI) offers the highest yield at 2. 2%, versus 1. 9% for Elevance Health Inc. (ELV).
09Is ELV or CI better for a retirement portfolio?
For long-horizon retirement investors, Cigna Corporation (CI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
35), 2. 2% yield, +124. 1% 10Y return). Both have compounded well over 10 years (CI: +124. 1%, ELV: +202. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ELV and CI?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.